1. INTRODUCTION
1.1. MARKET OVERVIEW
1.2. MARKET DEFINITION
1.3. SCOPE OF THE STUDY
1.4. CURRENCY
1.5. ASSUMPTIONS
1.6. BASE, AND FORECAST YEARS TIMELINE
2. RESEARCH METHODOLOGY
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. MARKET OVERVIEW AND SEGMENTATION
4.2. MARKET DRIVERS
4.3. MARKET RESTRAINTS
4.4. MARKET OPPORTUNITIES
4.5. PREVALENCE
4.5.1. BY AGE GROUP
4.5.2. BY REGION
4.6. PRODUCT PIPELINE
4.7. INNOVATIONS
5. CANCER THERAPEUTIC DRUGS MARKET BY INDICATION
5.1. SKIN CANCER
5.2. LUNG CANCER
5.3. BREAST CANCER
5.4. PROSTATE CANCER
5.5. OTHERS
6. CANCER THERAPEUTIC DRUGS MARKET BY PRODUCT TYPE
6.1. REVLIMID
6.2. AVASTIN
6.3. HERCEPTIN
6.4. RITUXAN
6.5. OTHERS
7. CANCER THERAPEUTIC DRUGS MARKET BY GEOGRAPHY
7.1. NORTH AMERICA
7.1.1. USA
7.1.2. CANADA
7.1.3. MEXICO
7.2. SOUTH AMERICA
7.2.1. BRAZIL
7.2.2. ARGENTINA
7.2.3. OTHERS
7.3. EUROPE
7.3.1. GERMANY
7.3.2. FRANCE
7.3.3. UNITED KINGDOM
7.3.4. SPAIN
7.3.5. OTHERS
7.4. MIDDLE EAST AND AFRICA
7.4.1. SAUDI ARABIA
7.4.2. ISRAEL
7.4.3. OTHERS
7.5. ASIA PACIFIC
7.5.1. CHINA
7.5.2. JAPAN
7.5.3. SOUTH KOREA
7.5.4. INDIA
7.5.5. OTHERS
8. COMPETITIVE INTELLIGENCE
8.1. COMPETITIVE BENCHMARKING AND ANALYSIS
8.2. RECENT INVESTMENTS AND DEALS
8.3. STRATEGIES OF KEY PLAYERS
9. COMPANY PROFILES
9.1. PFIZER INC.
9.2. CELGENE CORPORATION
9.3. F. HOFFMANN-LA ROCHE LTD
9.4. BRISTOL-MYERS SQUIBB COMPANY
9.5. NOVARTIS PHARMACEUTICALS CORPORATION
9.6. JANSSEN GLOBAL SERVICES, LLC
9.7. ELI LILLY AND COMPANY
9.8. MERCK & CO., INC.
9.9. ASTELLAS PHARMA INC.
LIST OF FIGURES
LIST OF TABLES